N-(3-(1H-tetrazol-5-yl)phenyl)-2,5-dimethylpyrrole | 862476-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(3-(1H-tetrazol-5-yl)phenyl)-2,5-dimethylpyrrole
• 英文别名: 5-[3-(2,5-dimethyl-1-pyrrolyl)phenyl]-2H-tetrazole；5-[3-(2,5-dimethylpyrrol-1-yl)phenyl]-2H-tetrazole
• CAS: 862476-45-7
• 化学式: C₁₃H₁₃N₅
• 分子量: 239.28
• InChiKey: HGXBKEFXSPFLOP-UHFFFAOYSA-N

物化性质

• 熔点：
  147-148 °C
• 沸点：
  467.6±47.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-(1H-tetrazol-5-yl)phenyl)-2,5-dimethylpyrrole 在 盐酸羟胺 、 potassium carbonate 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 48.0h， 生成 3-(2-甲基-2H-四唑-5-基)苯胺
  参考文献：
  名称：

  WO2007/60026

  摘要：

  公开号：
• 作为产物：
  描述：

  5-(3-氨基苯基)四唑 、 2,5-己二酮 在 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 1.5h， 以80%的产率得到N-(3-(1H-tetrazol-5-yl)phenyl)-2,5-dimethylpyrrole
  参考文献：
  名称：

  WO2007/60026

  摘要：

  公开号：

文献信息

• Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them
  申请人：Jary Helene

  公开号：US20070179134A1

  公开（公告）日：2007-08-02

  The present invention provides compounds of Formula (I): in which R 1 , R′ 1 , R 2 , R′ 2 , R 3 , and Y have the meanings given in the description are useful in the treatment of conditions susceptible to modulating ion channels, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.

  本发明提供了公式（I）的化合物：其中R1，R′1，R2，R′2，R3和Y具有描述中给出的含义，在调节离子通道易感病症的治疗中有用，以及它们的制备方法，通过药物的方式应用它们，以及包含它们的制药组合物。
• Design, Synthesis, and Biological Evaluation of <i>N</i>-Carboxyphenylpyrrole Derivatives as Potent HIV Fusion Inhibitors Targeting gp41
  作者：Kun Liu、Hong Lu、Ling Hou、Zhi Qi、Cátia Teixeira、Florent Barbault、Bo-Tao Fan、Shuwen Liu、Shibo Jiang、Lan Xie

  DOI：10.1021/jm800869t

  日期：2008.12.25

  On the basis of the structures of small-molecule hits targeting the HIV-1 gp41, N-(4-carboxy-3-hydi-oxy)plieiiyl-2,5-dimethylpyl-role (2, NB-2), and N-(3-carboxy-4-chloro)phenylpyrrole (A(1), NB-64), 42 N-carboxyphenylpyrrole derivatives in two categories (A and B series) were designed and synthesized. We found that I I compounds exhibited promising anti-HIV-1 activity at micromolar level and their antiviral activity was correlated with their inhibitory activity on gp41 six-helix bundle formation, suggesting that these compounds block HIV fusion and entry by disrupting gp41 core formation. The structure-activity relationship and molecular docking analysis revealed that the carboxyl group Could interact with either Arg579 or Lys574 to form salt bridges and two methyl groups on the pyrrole ring were favorable for interaction with the residues in gp41 pocket. The most active compound, N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrrole (A(12)), partially occupied the deep hydrophobic pocket, suggesting that enlarging the molecular size of A(12) could improve its binding affinity and anti-HIV-1 activity for further development as a small-molecule HIV fusion and entry inhibitor.
• UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS
  申请人：Proskelia SAS

  公开号：EP1965805A1

  公开（公告）日：2008-09-10
• US7875609B2
  申请人：——

  公开号：US7875609B2

  公开（公告）日：2011-01-25
• [EN] UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE L'URÉE UTILES COMME MODULATEURS DES RÉCEPTEURS DU CALCIUM
  申请人：PROSKELIA SAS

  公开号：WO2007060026A1

  公开（公告）日：2007-05-31

  [EN] The present invention provides compounds of formula (I): in which Y is oxygen or sulphur; R₁ and R_"1 are optionally substituted aryl, heteroaryl or a fused ring structure, R₂ and R_'2 are each H, or optionally substituted alkyl, alkylaminoalkyl or dialkylaminoalkyl, or R₂ and R_'2 and their N form a saturated or unsaturated optionally substituted heterocycle, R₃ represents a group of formula -(CH₂)P-Ar-Rn, wherein p is 0 or 1 and, when p is 1, is optionally substituted, Ar is aryl or heteroaryl, and each R is H, halogen; hydroxyl; trifiuoromethyl; linear and branched alkyl, alkenyl, alkynyl, and alkoxyl groups, all optionally further substituted by one or more of hydroxy groups, halogen atoms, alkoxy groups, amino groups, and alkylthio groups; linear and branched alkoxyl groups; linear and branched thioalkyl groups; aryl groups; aralkyl groups; aralkoxy groups; aryloxy groups; perfluoroalkyl; -CN; -NR₄R₅, -C(=X)NR₄R₅,-O-C(=X)NR₄R₅, -SO₂NR₄R₅, - Alk-NR₄R₅, -NZC(=X)(NH)_qR₆, -Alk-NZC(=X)(NH)_qR₆, -C(=X)R₆, -Alk-C(=X)(NH)_qR₆, -NHSO₂R₇, -SO₂R₇, -SOR₇, -SR₇, or is a saturated or unsaturated heterocyclyl group, and salts and esters thereof, are useful in the treatment of conditions susceptible to modulating ion channels, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.
  [FR] La présente invention concerne des composés de formule (I) : dans laquelle Y est un oxygène ou un soufre ; R1 et R\ sont chacun un aryle, ou hétéroaryle éventuellement substitué ou une structure cyclique fusionnée, R2 et R'2 sont chacun H ou un alkyle, alkylaminoalkyle ou dialkylaminoalkyle éventuellement substitué ou bien R2 et R'2 et leurs N forment un hétérocycle saturé ou insaturé éventuellement substitué, R3 représente un groupe de formule -(CH₂)_p-Ar-R_n, p valant 0 ou 1 et le groupe étant éventuellement substitué lorsque p vaut 1, Ar étant un aryle ou un hétéroaryle et chaque R étant H ou un halogène ; un hydroxyle ; un trifulorométhyle ; des groupes alkyle, alcényle, alcynyle et alcoxy linéaires et ramifiés, tous étant éventuellement en plus substitués par un ou plusieurs groupes hydroxy, atomes d'halogène, groupes alcoxy, groupes amino et groupes alkylthio ; des groupes alcoxy linéaires et ramifiés ; des groupes thioalkyle linéaires et ramifiés ; des groupes aryle ; des groupes aralkyle ; des groupes aralcoxy ; des groupes aryloxy ; un perfluoroalkyle.